Brand : Atavir
Ingredients : Atazanavir
Strength : 300mg
Manufactured : Cipla
Package : 30 Tablets
Atazanavir should not used alone; it should be combined with ritonavir which is majorly prescribed for therapy experienced adult patients with preceding virologic failure. The higher dose of ritonavir will cause reducing the safety profile of atazanavir. Before starting the treatment with atazanavir; Patients who are going to receiving the atazanavir should be performed with renal function test periodically for both prior and during the therapy. Serum creatinine, creatinine clearance, urine analysis should be checked frequently. Hepatic function test is also performed before starting & during the treatment. In adults: The prescribed dose of Atavir is one tablet should be administered as a single dose by combining with any of the following drugs like; Tenofovir H2 receptor antagonist: The gastric regulator drug should not be exceeding a dose equal to famotidine 40mg as two times a day. Atavir tablets should be concurrently administered with & or at least 10 hours after the dose of H2 receptor antagonist. Proton pump inhibitors: The administration of proton pump inhibitor should not superior a dose equal to Omeprazole 20mg and it should be taken 12 hours before the dose of Atavir tablets.In therapy experienced patients (adults)
The recommended dose is one tablet of Atazanavir 300mg and Ritonavir 100mg should be administered as a single dose. Combination therapy: The recommended dose in combination with both H2RA and Tenofovir DF is 400mg of atazanavir and 100mg of Ritonavir given once daily. H2 receptor antagonist: The gastric regulator drug should not be exceeding a dose equal to famotidine 20mg as two times a day. Atavir tablets should be concurrently administered with & or at least 10 hours after the dose of H2 receptor antagonist. If patient taking H2 receptor antagonist, Atavir tablets should be taken with food. If patients administered tenofovir & H2 receptor antagonist concurrently, then Atavir tablets should not be recommend. In therapy experienced patients who are getting Atavir tablets, proton pump inhibitor should not be recommended.
The usual dose is Atazanavir 300mg and Ritonavir 100mg given once daily. If patients unable to tolerate Ritonavir administrate single dose of Atazanavir 400mg. When in combination with Efavirenz then administrate Atazanavir 400mg and Ritonavir 100mgIn pregnant women
The recommended dose of Atavir is; In both new commenced or already treated patients: The prescribed dose is one Atavir tablet should be administered as a single dose. In case of combination of H2RA or tenofovir DF, the recommended dose is 400mg of atazanavir & 100mg of ritonavir should be recommended as a single dose. In therapy experienced pregnant patients during 2nd or 3rd trimester, atazanavir should not be suggested.In renal impairment
In severe renal damage patients who are not tolerated to hemodialysis, no dosage adjustment should be recommended. In therapy naïve patients with final stage of renal disease, the dose of Atavir tablets should be reduced. In HIV experienced patients with final stage of renal disease, the Atavir tablets should not be recommended.In hepatic impairment
For mild to moderate liver damaged patients, Atavir tablets should be recommended Atavir 400mg and Atavir 300mg for administration. In severe condition, Atavir tablets should not be used.Administration
Atavir tablets should be administered with food. Atavir tablets are fixed dose combination; it should not be broke, chew or crush.Over dosage
In Atavir over dosage condition patient should be; Provide with supportive measures Gastric lavage or emesis should be provided Activated charcoal is used for removing the unabsorbed dose of Atavir Dialysis is not successive, because ritonavir is highly metabolized and binds to human plasma protein in higher extent.
The major adverse effects of Atavir tablets are; Cardiac conduction abnormalities Rash Increased bilirubin levels Chronic kidney disease Nephrolithiasis CholelithiasisThe common side effects
Jaundice Scleral icterus Diarrhea Rashes Depression Myalgia Increased AST, ALT Increased lipase Increased creatine kinase Neutropenia Increased triglycerides Decreased plateletsPost marketing reports
Edema Pancreatitis Liver function abnormalities Diabetes mellitus Arthralgia Alopecia Maculopapular rash Angioedema Pruritus
This is due to prolonged elevation of PR intervals by atazanavir. Monitor with ECG frequently for reducing the adverse effects.Diabetes mellitus
Check the blood glucose level periodically Patient must be prescribed with dose adjustment insulin or oral hypoglycemic agents. Diabetes ketoacidosis should be occurred after discontinue the treatment. Immune reconstitution syndrome: Stop the Atavir therapy. Redistribution of fat occurred in the body leads to cause obesity. To overcome the problem in severe condition, discontinue the treatment.Increased bilirubin
Symptomatic elevation of bilirubin occurs by prohibits the UDP glucuronosyl transferase. Dose reduction is not possible, once the level of bilirubin is elevates stop the treatment.Skin reactions
Rash is the one of the most important effect occurred on skin. Atazanavir should be stopped during rashes present.Kidney disease
During the Atavir treatment patient should be monitored with renal function test. Nephrolithiasis & cholelithiasis: To overcome the problem, patient must be provided with additional management. Temporary postponement or discontinuation of therapy is occurring. Adverse effects may occur due to drug interactions, like; Atavir with drugs are metabolized by CYP3A or CYP3A causes increased concentration of these drugs.Hemophilia
Severe bleeding occurs, discontinue the protease inhibitor therapy.